Maryland company targets revolutionary change to orthopedic surgery
COLUMBIA, Md., (January 24, 2025) — TEDCO, Maryland’s economic engine for technology companies, announced a recent $250,000 Builder Fund investment in Nostopharma, a musculoskeletal therapeutic platform company focused on treating complications of trauma, orthopedic surgery and rare diseases musculoskeletal sequalae. TEDCO’s Builder Fund operates under the umbrella of Social Impact Funds and not only provides companies with investment funds but also offers various resources, including executive support, mentorship and assorted networking opportunities.
“Nostopharma’s goal is simple: to restore the health of patients recovering from any kind of musculoskeletal trauma and create products that minimize any complications of that recovery from the beginning. We put patients’ needs first and what patients want is to avoid painful and costly revision surgeries,” said company CEO Ekaterina Vert-Wong. “With TEDCO’s generous support and comprehensive resources for startups, we are making significant strides toward achieving that goal.”
Nostopharma, based in Bethesda, Md., aims to address the gap in post-trauma care with its platform - NPnano. Their first product NP102nano, a simple application administered during surgical procedures, has the potential to reduce complication rates and costly revision surgeries in 90% of acetabular fractures and 50% of elbow traumas.
“The product they have constructed focuses on a more efficient and less invasive process for orthopedic surgeries,” said Jean-Luc Park, senior director of Social Impact Funds. “Technology companies with the same, unfaltering drive as Nostopharma reflect the dedication and innovation that TEDCO seeks to invest in. As stewards of state funds, the investment team aims to build a market-rate portfolio.”
For more information, visit our page at www.tedcomd.com/funding.